BRISBANE, Calif.--(BUSINESS WIRE)--Delpor, Inc. (Delpor), a clinical stage biopharmaceutical company that utilizes innovative technologies to develop once-yearly therapeutics for chronic conditions, today announced that it has initiated and dosed the first subjects in a phase 1 clinical trial of DLP-160, a 6-12-month formulation of naltrexone for the treatment of opioid use disorder (OUD). This is an open-label study in healthy volunteers to evaluate the safety, tolerability, and pharmacokinetics of naltrexone when administered in sequence of Naltrexone HCL (Oral), DLP-160 (Naltrexone Implant), followed by Vivitrol® (Intramuscular).